Salvia BioElectronics
- Company typePrivate
- Founded2017
- HeadquartersEindhoven, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Salvia BioElectronics does
Salvia BioElectronics B.V. is a clinical-stage medical device company founded in 2017 in Eindhoven, Netherlands, developing MySalvia Therapy, an implantable neuromodulation system for patients with resistant chronic migraine and chronic cluster headache. The therapy consists of two ultra-thin bioelectronic foil implants placed subcutaneously over the supra-orbital and occipital nerves, paired with an external wearable activator that delivers on-demand, patient-triggered electrical stimulation. The product has received FDA Breakthrough Device Designation and is the subject of the first FDA IDE-approved implantable neuromodulation pivotal trial in resistant migraine (RECLAIM), with parallel clinical studies (RELIEF, RESPONSE, RESPONSE-II) underway in the Netherlands, Belgium, and Australia, and a planned U.S. study.
The company targets a large underserved population: more than one billion people worldwide live with migraine, with resistant chronic migraine defined as persistent disability despite multiple preventive treatments. Cluster headache, the secondary indication, affects approximately 1 in 1,000 people and is treated as an orphan-class neurological condition. Salvia's go-to-market strategy is direct enterprise sales to headache specialists, neurologists, and hospital systems once regulatory approvals are obtained, with field sales leadership now being built out for the U.S. market under a newly appointed VP of U.S. Commercial Strategy and Operations.
Salvia has raised approximately €81 million in cumulative funding, including a $60 million (€53 million) oversubscribed Series B in May 2025 led by Innovation Industries with participation from Invest-NL, the EIC Fund, Inkef, Panakès Partners, SHS Capital, Thuja Capital, BOM, and Dolby Family Ventures. The company employs more than 70 people across 19 nationalities and is actively investing in an adjacent AI-driven closed-loop neurostimulation research initiative (CLUSTERSENSE) in partnership with Mentech Engineering and Leiden University Medical Center. As of the latest data, Salvia is pre-revenue, with all monetization contingent on regulatory approvals in the U.S., Europe, and Australia.
Salvia BioElectronics firmographics
Firmographics- Name
- Salvia BioElectronics
- Legal name
- Salvia BioElectronics B.V.
- Website
- https://salviabioelectronics.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Salvia BioElectronics industry classification
Industry- Product category
- Implantable Neuromodulation Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industry
- Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)
Keywords
Where Salvia BioElectronics is headquartered
LocationHeadquarters
- HQ city
- Eindhoven
- HQ country
- Netherlands
- HQ region
- Europe
Offices2 records
Markets served
Salvia BioElectronics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- MySalvia Therapy (Implant-based Neuromodulation): The company is developing an implantable neuromodulation therapy for chronic migraine and cluster headache. It is currently in clinical stage and not yet approved for commercial use. Revenue will be generated through product sales of the implant system and wearable device upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Salvia BioElectronics product offering
Product offeringCore offering
Salvia BioElectronics is developing MySalvia Therapy, an investigational neuromodulation system for chronic migraine and cluster headache. The system consists of two ultra-thin implants placed beneath the skin at the supra-orbital and occipital nerve regions, paired with an external wearable device (MySalvia Device) that patients activate on demand by pressing a button to deliver targeted electrical stimulation to craniofacial nerves. The therapy is currently in clinical trials (RELAIM, RECLAIM, RESPONSE, RESPONSE-II) and is not yet approved for commercial use.
Product overview
Salvia BioElectronics is a clinical-stage medical device company pioneering a single neuromodulation therapy — MySalvia Therapy — for people with resistant chronic migraine and cluster headache. MySalvia Therapy consists of two ultra-thin implantable neurostimulators (placed at the supraorbital and occipital nerve regions) paired with an external wearable device (MySalvia Device) that the patient activates on demand via button press to deliver targeted electrical stimulation. The therapy is designed to reduce migraine attack frequency and intensity by targeting key craniofacial nerves. It is currently investigational, evaluated across multiple clinical studies (RELIEF, RECLAIM, RESPONSE, RESPONSE-II) in Belgium, the Netherlands, Australia, and the United States, and is not yet approved for commercial use. The company is also exploring adaptive, data-informed use of its technology through the CLUSTERSENSE research initiative.
Differentiator
Problem solved
Functional benefit
Products and services
- MySalvia Therapy An implantable neuromodulation system for resistant chronic migraine and chronic cluster headache, consisting of two ultra-thin implants placed beneath the skin of the forehead and back of the head (at the supra-orbital and occipital nerve regions) plus an external wearable controller (MySalvia Device) that patients activate on demand to deliver targeted electrical stimulation to craniofacial nerves. Designed for patients who have failed multiple preventive treatments.
Quantifiable outcome
- MySalvia Therapy is being evaluated in clinical trials (RECLAIM, RELIEF, RESPONSE, RESPONSE-II) for safety and effectiveness in reducing migraine/cluster headache frequency and severity
Companies that use Salvia BioElectronics
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles1 record
Salvia BioElectronics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature4 records
Salvia BioElectronics partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and supporting.
- Mentech EngineeringcoreCollaboration in CLUSTERSENSE project (October 2025 - September 2028) developing AI-driven pain recognition system integrated with Salvia's neurostimulation technology. Mentech's HUME platform captures physiological signals for AI-based pattern recognition.
- Leiden University Medical Center (LUMC)coreCLUSTERSENSE project partner providing clinical expertise and access to well-characterized patient populations for validating AI models and translating results into clinical practice for cluster headache treatment.
- Erasmus MC RotterdamcoreClinical trial site for RECLAIM migraine study in the Netherlands.
- St. Antonius Hospital NieuwegeincoreClinical trial site for RECLAIM migraine study in the Netherlands.
- AZ Delta RoeselarecoreClinical trial site in Belgium, first in Europe to implant patients with Salvia's bioelectronic foil for severe migraine.
- ZAS AntwerpsupportingClinical trial site for RECLAIM migraine study in Belgium.
- Jessa Hospital HasseltsupportingClinical trial site for RECLAIM migraine study in Belgium.
- AZ Sint-Jan BrugessupportingClinical trial site for RECLAIM migraine study in Belgium.
- AZ Groeninge KortrijksupportingClinical trial site for RECLAIM migraine study in Belgium.
- AZ OostendesupportingClinical trial site for RECLAIM migraine study in Belgium.
Scale indicators7 records
Recent moves6 records
Expansion highlights7 records
Salvia BioElectronics competitors and assessment
Company assessmentDirect peers
- electroCore: electroCore markets gammaCore, a non-invasive vagus nerve stimulation (nVNS) therapy approved for migraine and cluster headache. Directly comparable as a neuromodulation therapy targeting the same primary indications as MySalvia, though delivered externally rather than via implants.
- Theranica Bio-Electronics: Theranica manufactures Nerivio, a wearable remote electrical neuromodulation (REN) device FDA-cleared for acute and preventive migraine. Direct competitor in the migraine neuromodulation space using a non-invasive wearable form factor versus Salvia's implantable approach.
- Cefaly Technology: Cefaly produces an external trigeminal nerve stimulation device FDA-cleared for migraine prevention. Competitor in transcutaneous supraorbital nerve stimulation for migraine, addressing the same nerve territory Salvia targets with its implant.
- Nevro: Nevro markets the HF10 high-frequency spinal cord stimulation system for chronic pain. Compares as a neuromodulation implantable device company targeting chronic pain, and Salvia's new VP U.S. Commercial came directly from Nevro's senior leadership.
Broad incumbents
- Abbott (Neuromodulation): Abbott's Neuromodulation division offers Proclaim XR, Proclaim DRG and other implantable neurostimulators for chronic pain and movement disorders. Broad incumbent in implantable neuromodulation with overlap in therapy category, channel (neurologists/pain physicians), and commercial model.
- Medtronic (Neuromodulation): Medtronic offers Activa, Intellis, Vanta and other implantable neurostimulators across pain, DBS, and sacral neuromodulation. Large incumbent with adjacent technology, established clinical evidence in neuromodulation, and competing for the same hospital purchasing committees.
- Boston Scientific (Neuromodulation): Boston Scientific markets Precision Spectra, WaveWriter Alpha and other SCS systems plus Vercise DBS. Comparable as an established implantable neuromodulation incumbent with broad indications, commercial reach, and R&D pipeline that could expand into migraine.
- LivaNova: LivaNova offers VNS Therapy for epilepsy and depression via implantable pulse generators. Compares as an incumbent implantable neuromodulation company that has explored cranial nerve stimulation indications adjacent to Salvia's craniofacial approach.
Emerging players
- Saluda Medical: Saluda Medical developed the Evoke closed-loop spinal cord stimulation system with objective neural response measurement. Comparable as a smaller neuromodulation player pursuing AI/closed-loop neurostim technology, similar in spirit to Salvia's CLUSTERSENSE adaptive initiative.
- Mainstay Medical: Mainstay Medical commercializes the ReActiv8 restorative neurostimulation system for chronic mechanical low back pain. Comparable as a clinical-to-commercial stage implantable neuromodulation company targeting chronic pain indications with a similar go-to-market profile.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Salvia BioElectronics social profiles
Digital presenceSalvia BioElectronics compliance and trust
Trust signalCompliance2 records
Salvia BioElectronics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Salvia BioElectronics leadership team
Management profileNumber of profiles
Profiles14 records
Salvia BioElectronics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Salvia BioElectronics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Salvia BioElectronics
What does Salvia BioElectronics do?
Salvia BioElectronics is developing MySalvia Therapy, an investigational neuromodulation system for chronic migraine and cluster headache. The system consists of two ultra-thin implants placed beneath the skin at the supra-orbital and occipital nerve regions, paired with an external wearable device (MySalvia Device) that patients activate on demand by pressing a button to deliver targeted electrical stimulation to craniofacial nerves. The therapy is currently in clinical trials (RELAIM, RECLAIM, RESPONSE, RESPONSE-II) and is not yet approved for commercial use.
Is Salvia BioElectronics a public or private company?
Salvia BioElectronics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Salvia BioElectronics founded?
Salvia BioElectronics was founded in 2017. It employs 11 to 50 people.
Where is Salvia BioElectronics based?
Salvia BioElectronics is headquartered in Eindhoven, Netherlands, in the Europe region.
How does Salvia BioElectronics make money?
One revenue line is on record: mySalvia Therapy (Implant-based Neuromodulation).
Who are Salvia BioElectronics's main competitors?
Direct peers on record are electroCore, Theranica Bio-Electronics, Cefaly Technology and Nevro. Broad incumbents are Abbott (Neuromodulation), Medtronic (Neuromodulation), Boston Scientific (Neuromodulation) and LivaNova. Emerging players are Saluda Medical and Mainstay Medical.
Does Salvia BioElectronics have an API?
No public API is recorded for Salvia BioElectronics.
What industry is Salvia BioElectronics in?
Salvia BioElectronics's product category is Implantable Neuromodulation Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAKAIAM, Pain Medicine (Interventional/Neuropathic Pain). Its NAICS code is 334510 and its SIC code is 3845.